Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Volume 24, Issue 17
  5. Article
Volume 24, Issue 17
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Purpose

The aim was to evaluate the safety and effectiveness of PTCD combined with TACE in the treatment of hepatocellular carcinoma with obstructive jaundice and to compare the efficacy of TACE in patients with different levels of bilirubin after PTCD.

Methods

The clinical data of 141 patients with HCC complicated with obstructive jaundice were analyzed retrospectively. The patients underwent PTCD first. When the total bilirubin decreased, the patients received TACE or Apatinib treatment. They were divided into two groups: (1) PTCD+TACE group, N=68; (2) PTCD+Apatinib group, N=73.

Results

The PTCD+TACE group had higher ORR and DCR than the PTCD+Apatinib group (57.4% 12.3%, < 0.001; 80.9% 60.3%, = 0.010). The mPFS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group (7.1 months 3.8 months, < 0.001). The mOS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group(11.5 months 7.7 months, < 0.001). In the subgroup analysis of the PTCD+TACE group, the results showed that the survival benefits of the groups with total bilirubin <2 times and 2-3 times were greater.

Conclusion

In patients with HCC and obstructive jaundice, superselective TACE(lipiodol+epirubicin emulsion) significantly prolonged OS and PFS compared with Apatinib after using PTCD to reduce total bilirubin to <100 μmol/L. Patients whose total bilirubin dropped to ≤3 times of the upper limit of normal value after PTCD had longer OS and PFS than patients >3 times.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206313132240712101607
2024-10-01
2025-06-20

  • From This Site

    /content/journals/acamc/10.2174/0118715206313132240712101607
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Chidambaranathan-ReghupatyS. FisherP.B. SarkarD. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.Adv. Cancer Res.202114916110.1016/bs.acr.2020.10.001 33579421
     [Google Scholar]
  2. KulikL. El-SeragH.B. Epidemiology and management of hepatocellular carcinoma.Gastroenterology20191562477491.e110.1053/j.gastro.2018.08.065 30367835
     [Google Scholar]
  3. YangJ.D. HainautP. GoresG.J. AmadouA. PlymothA. RobertsL.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management.Nat. Rev. Gastroenterol. Hepatol.2019161058960410.1038/s41575‑019‑0186‑y 31439937
     [Google Scholar]
  4. DimitroulisD. DamaskosC. ValsamiS. DavakisS. GarmpisN. SpartalisE. AthanasiouA. MorisD. SakellariouS. KykalosS. TsourouflisG. GarmpiA. DelladetsimaI. KontzoglouK. KouraklisG. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.World J. Gastroenterol.201723295282529410.3748/wjg.v23.i29.5282 28839428
     [Google Scholar]
  5. WooH.Y. HanS.Y. HeoJ. KimD.U. BaekD.H. YooS.Y. KimC.W. KimS. SongG.A. ChoM. KangD.H. Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice.PLoS One20171211e018746910.1371/journal.pone.0187469 29095941
     [Google Scholar]
  6. MinamiY. KudoM. Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage.Dig. Dis.201230659259710.1159/000343087 23258100
     [Google Scholar]
  7. QinL.X. TangZ.Y. Hepatocellular carcinoma with obstructive jaundice: Diagnosis, treatment and prognosis.World J. Gastroenterol.20039338539110.3748/wjg.v9.i3.385 12632482
     [Google Scholar]
  8. SuhY.G. KimD.Y. HanK.H. SeongJ. Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice.Gut Liver20148552653510.5009/gnl13370 25071072
     [Google Scholar]
  9. ParkS. ParkJ.Y. ChungM.J. ChungJ.B. ParkS.W. HanK.H. SongS.Y. BangS. The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma.Yonsei Med. J.20145551267127210.3349/ymj.2014.55.5.1267 25048484
     [Google Scholar]
  10. TanakaT. KuzuyaT. IshigamiM. ItoT. IshizuY. HondaT. IshikawaT. FujishiroM. Efficacy and safety of sorafenib in unresectable hepatocellular carcinoma with bile duct invasion.Oncology202098962162910.1159/000507051 32434180
     [Google Scholar]
  11. LaiE.C.H. Yee LauW. Hepatocellular carcinoma presenting with obstructive jaundice.ANZ J. Surg.200676763163610.1111/j.1445‑2197.2006.03794.x 16813631
     [Google Scholar]
  12. GalleP.R. FornerA. LlovetJ.M. MazzaferroV. PiscagliaF. RaoulJ-L. SchirmacherP. VilgrainV. European association for the study of the liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma.J. Hepatol.201869118223610.1016/j.jhep.2018.03.019 29628281
     [Google Scholar]
  13. SugiyamaG. OkabeY. IshidaY. SaitouF. KawaharaR. IshikawaH. HoriuchiH. KinoshitaH. TsurutaO. SataM. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma.World J. Gastroenterol.201420226968697310.3748/wjg.v20.i22.6968 24944490
     [Google Scholar]
  14. AnJ. LeeK.S. KimK.M. ParkD.H. LeeS.S. LeeD. ShimJ.H. LimY.S. LeeH.C. ChungY.H. LeeY.S. Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.Clin. Mol. Hepatol.201723216016910.3350/cmh.2016.0088 28506055
     [Google Scholar]
  15. ReigM. FornerA. RimolaJ. Ferrer-FàbregaJ. BurrelM. Garcia-CriadoÁ. KelleyR.K. GalleP.R. MazzaferroV. SalemR. SangroB. SingalA.G. VogelA. FusterJ. AyusoC. BruixJ. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J. Hepatol.202276368169310.1016/j.jhep.2021.11.018 34801630
     [Google Scholar]
  16. NaS.K. YimS.Y. SuhS.J. JungY.K. KimJ.H. SeoY.S. YimH.J. YeonJ.E. ByunK.S. UmS.H. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma.J. Surg. Oncol.2018117591292110.1002/jso.24992 29448306
     [Google Scholar]
  17. HanK. KimJ.H. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.World J. Gastroenterol.20152136103271033510.3748/wjg.v21.i36.10327 26420959
     [Google Scholar]
  18. GoldsteinH.M. WallaceS. AndersonJ.H. BreeR.L. GianturcoC. Transcatheter occlusion of abdominal tumors.Radiology1976120353954510.1148/120.3.539 948584
     [Google Scholar]
  19. PetruzziP. CrocettiL. LencioniR. Chemoembolization of hepatocellular carcinoma. Semin. Intervent. Radiol.,201330100301110.1055/s‑0033‑133364824436512
     [Google Scholar]
  20. SieghartW. HuckeF. Peck-RadosavljevicM. Transarterial chemoembolization: Modalities, indication, and patient selection.J. Hepatol.20156251187119510.1016/j.jhep.2015.02.010 25681552
     [Google Scholar]
  21. LiS. HeX. DangL. XuF. FangJ. LiF. WangW. Efficacy of 125I versus Non-125I combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice.Dig. Dis. Sci.201863232132810.1007/s10620‑017‑4899‑x 29305738
     [Google Scholar]
  22. YoungS. SanghviT. LakeJ.J. RubinN. GolzarianJ. Predicting post-transarterial chemoembolization outcomes: A comparison of direct and total bilirubin serums levels.Diagn. Interv. Imaging2020101635536410.1016/j.diii.2019.12.006 31948887
     [Google Scholar]
  23. ThoratA. LeeC.F. WuT.H. ChanK.M. ChouH.S. LeeW.C. Safety of transarterial chemoembolization as bridging therapy in HCC patients with hyperbilirubinemia on the waiting list for liver transplantation: A centre experience.Hepatogastroenterology20136012820762079 24719950
     [Google Scholar]
  24. ChandrashekharaS.H. GamanagattiS. SinghA. BhatnagarS. Current status of percutaneous transhepatic biliary drainage in palliation of malignant obstructive jaundice: A review.Indian J. Palliat. Care201622437838710.4103/0973‑1075.191746 27803558
     [Google Scholar]
  25. SunJ.J. WangK. ZhangC.Z. GuoW.X. ShiJ. CongW.M. WuM.C. LauW.Y. ChengS.Q. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion.Ann. Surg. Oncol.20162341344135110.1245/s10434‑015‑5008‑z 26714945
     [Google Scholar]
  26. LlovetJ.M. LencioniR. mRECIST for HCC: Performance and novel refinements.J. Hepatol.202072228830610.1016/j.jhep.2019.09.026 31954493
     [Google Scholar]
  27. TianT. GuoJ. HuJ.L. HuY. GuoP. YuX.Y. Advanced hepatocellular carcinoma and palliative care: a scoping review.BMJ Support. Palliat. Care202214216317010.1136/spcare‑2022‑003798 36396345
     [Google Scholar]
  28. RammohanA. SathyanesanJ. RajendranK. PitchaimuthuA. PerumalS.K. BalaramanK. RamasamyR. PalaniappanR. GovindanM. Bile duct thrombi in hepatocellular carcinoma: Is aggressive surgery worthwhile?HPB (Oxford)201517650851310.1111/hpb.12383 25639610
     [Google Scholar]
  29. FargoM.V. GroganS.P. SaguilA. Evaluation of jaundice in adults.Am. Fam. Physician2017953164168 28145671
     [Google Scholar]
  30. BhattaraiS. GrahamR.P. SigelC.S. ShiJ. GonzalezR.S. XueY. KrasinskasA.M. HooKim, K.; Adsay, V.; Reid, M.D. Bile duct involvement by hepatocellular carcinoma: A rare occurrence and poor prognostic indicator in bile duct brushing samples.Cancer Cytopathol.20191271169169910.1002/cncy.22185 31518056
     [Google Scholar]
  31. JeonSH. ParkKS. KimYH. ShinYS. KangMK. JangBK. ChungWJ. ChoKB. HwangJS. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma.Korean J. Gastroenterol.200750317618210.1111/ecc.12858 17885283
     [Google Scholar]
  32. TongD. WuL. ChenX. LiY. Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice.Eur. J. Cancer Care (Engl.)2018274e1285810.1111/ecc.12858 29767833
     [Google Scholar]
  33. ZhangC. YangY. WuP. MaY. ZhangH. LinM. ShiL. LiJ. ZhaoM. Prevention and treatment of complications for full-covered self-expanding removable metal stents in malignant obstructive jaundice.Zhonghua Yi Xue Za Zhi2015956416419 25916776
     [Google Scholar]
  34. SaccoR. TapeteG. SimonettiN. SellitriR. NataliV. MelissariS. CabibboG. BiscagliaL. BresciG. GiacomelliL. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A review.J. Hepatocell. Carcinoma2017410511010.2147/JHC.S103661 28795053
     [Google Scholar]
  35. KhalidM.A. AchakzaiI.K. HanifF.M. AhmedS. MajidZ. LuckN.H. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma.Gastroenterol. Hepatol. Bed Bench2019122110115 31191834
     [Google Scholar]
  36. LiL. MoF. HuiE.P. ChanS.L. KohJ. TangN.L.S. YuS.C.H. YeoW. The association of liver function and quality of life of patients with liver cancer.BMC Gastroenterol.20191916610.1186/s12876‑019‑0984‑2 31046687
     [Google Scholar]
  37. TellapuriS. SutphinP.D. BegM.S. SingalA.G. KalvaS.P. Staging systems of hepatocellular carcinoma: A review.Indian J. Gastroenterol.201837648149110.1007/s12664‑018‑0915‑0 30593649
     [Google Scholar]
  38. BruixJ. ReigM. ShermanM. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.Gastroenterology2016150483585310.1053/j.gastro.2015.12.041 26795574
     [Google Scholar]
  39. Díaz-GonzálezÁ. ReigM. BruixJ. Treatment of hepatocellular carcinoma.Dig. Dis.201634559760210.1159/000445275 27332893
     [Google Scholar]
  40. LiangX. LiangliangX. PengW. TaoY. JinfuZ. MingZ. MingqingX. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients.Sci. Rep.20211111462410.1038/s41598‑021‑94035‑5 34272447
     [Google Scholar]
  41. BrownD.B. FundakowskiC.E. Lisker-MelmanM. CrippinJ.S. PilgramT.K. ChapmanW. DarcyM.D. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.J. Vasc. Interv. Radiol.200415111209121810.1097/01.RVI.0000128123.04554.C1 15525739
     [Google Scholar]
  42. CabibboG. GencoC. Di MarcoV. BarbaraM. EneaM. ParisiP. BrancatelliG. RomanoP. CraxìA. CammàC. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.Aliment. Pharmacol. Ther.201134219620410.1111/j.1365‑2036.2011.04694.x 21564144
     [Google Scholar]
  43. ChoiJ. RyuJ.K. LeeS.H. AhnD.W. HwangJ.H. KimY.T. YoonY.B. HanJ.K. Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach.Hepatobiliary Pancreat. Dis. Int.201211663664210.1016/S1499‑3872(12)60237‑9 23232636
     [Google Scholar]
  44. ChoH.C. LeeJ.K. LeeK.H. LeeK.T. PaikS. ChooS.W. DoY.S. ChooI.W. Are endoscopic or percutaneous biliary drainage effective forobstructive jaundice caused by hepatocellular carcinoma?Eur. J. Gastroenterol. Hepatol.201123322423110.1097/MEG.0b013e3283436ff6 21228705
     [Google Scholar]
  45. BaoG. LiuH. MaY. LiN. LvF. DongX. ChenX. The clinical efficacy and safety of different biliary drainages in malignant obstructive jaundice treatment.Am. J. Transl. Res.202113674007405 34306512
     [Google Scholar]
  46. AlatiseO. OwojuyigbeA. OmisoreA. NdububaD. AburimeE. DuaK. AsombangA. Endoscopic management and clinical outcomes of obstructive jaundice.Niger. Postgrad. Med. J.202027430231010.4103/npmj.npmj_242_20 33154282
     [Google Scholar]
  47. ZeremE. ImširovićB. KunosićS. ZeremD. ZeremO. Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction.Clin. Exp. Hepatol.202281707710.5114/ceh.2022.114190 35415254
     [Google Scholar]
  48. DuanF. CuiL. BaiY. LiX. YanJ. LiuX. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: A systematic review and meta-analysis.Cancer Imaging20171712710.1186/s40644‑017‑0129‑1 29037223
     [Google Scholar]
  49. RizzoA. RicciA.D. FregaG. PalloniA. De LorenzoS. AbbatiF. MollicaV. TavolariS. Di MarcoM. BrandiG. How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis.In Vivo20203441701171410.21873/invivo.11964 32606139
     [Google Scholar]
  50. LiuY.M. RenY.Q. SongS.L. ZhengC.S. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: Etiological characteristics, treatment, and outcome analysis.Kaohsiung J. Med. Sci.202210.1002/kjm2.12613 36354204
     [Google Scholar]
  51. LvW.F. LuD. HeY.S. XiaoJ.K. ZhouC.Z. ChengD.L. Liver abscess formation following transarterial chemoembolization.Medicine (Baltimore)20169517e350310.1097/MD.0000000000003503 27124055
     [Google Scholar]
  52. ScartozziM. BaroniG.S. FaloppiL. PaoloM.D.P. PierantoniC. CandelariR. BerardiR. AntognoliS. MincarelliC. RisalitiA. MarmoraleC. AnticoE. BenedettiA. CascinuS. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: Efficacy and safety results from a large mono-institutional analysis.J. Exp. Clin. Cancer Res.201029116410.1186/1756‑9966‑29‑164 21159184
     [Google Scholar]
  53. MohammadifardM. GhanaatiH. MohammadifardM. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma.J. Family Med. Prim. Care202110103553356010.4103/jfmpc.jfmpc_2347_20 34934646
     [Google Scholar]
  54. DaiQ.S. GuH.L. YeS. ZhangY.J. LinX.J. LauW.Y. PengZ.W. ChenM.S. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study.Mol. Clin. Oncol.2014261047105410.3892/mco.2014.391 25279196
     [Google Scholar]
  55. KongJ.Y. LiS.M. FanH.Y. ZhangL. ZhaoH.J. LiS.M. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma.Medicine (Baltimore)20189733e1187210.1097/MD.0000000000011872 30113483
     [Google Scholar]
  56. LuJ. ZhaoM. AraiY. ZhongB.Y. ZhuH.D. QiX.L. BaereT. PuaU. YoonH.K. MadoffD.C. TengG.J. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: Consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).Hepatobiliary Surg. Nutr.202110566167110.21037/hbsn‑21‑260 34760969
     [Google Scholar]
  57. LeeJ.W. HanJ.K. KimT.K. ChoiB.I. ParkS.H. KoY.H. YoonC.J. YeonK.M. Obstructive jaundice in hepatocellular carcinoma: response after percutaneous transhepatic biliary drainage and prognostic factors.Cardiovasc. Intervent. Radiol.200225317617910.1007/s00270‑001‑0100‑0 12058212
     [Google Scholar]
  58. ParkK.H. KimJ.H. ChoeW.H. KwonS.Y. YooB.C. HwangJ.H. ParkS.W. KimY.J. ParkH.S. YuM.H. JeonH.J. Risk factors for liver function deterioration after transarterial chemoembolization refractoriness in child-pugh class a hepatocellular carcinoma patients.Korean J. Gastroenterol.202075314715610.4166/kjg.2020.75.3.147 32209803
     [Google Scholar]
  59. ChenY. YanZ.P. WangJ.H. WangX.L. ChengJ.M. GongG.Q. LiuQ.X. QianS. LiuR. LuoJ.J. Epirubicin in the treatment of malignant obstructive jaundice.Zhonghua Zhong Liu Za Zhi2006285397399 17045011
     [Google Scholar]
  60. LiM.Q. ZhangJ.X. LuC.H. PanH. RuF.M. CaoC.W. XuJ.C. XuJ.H. Long-term outcome of interventional therapy for malignant biliary obstruction: A retrospective analysis of 109 cases.Zhonghua Yi Xue Za Zhi2008883927432747 19080446
     [Google Scholar]
  61. TianS. QuanH. XieC. GuoH. LüF. XuY. LiJ. LouL. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.Cancer Sci.201110271374138010.1111/j.1349‑7006.2011.01939.x 21443688
     [Google Scholar]
  62. YuW.C. ZhangK.Z. ChenS.G. LiuW.F. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma.Medicine (Baltimore)2018973e970410.1097/MD.0000000000009704 29505026
     [Google Scholar]
  63. WangY. GouQ. XuR. ChenX. ZhouZ. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: A comparative retrospective study.OncoTargets Ther.2018113407341310.2147/OTT.S161023 29928132
     [Google Scholar]
  64. ZhenL. JialiC. YongF. HanX. HongmingP. WeidongH. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: A retrospective study.J. Cancer20189162773277710.7150/jca.26376 30123344
     [Google Scholar]
  65. HuY. LinH. HaoM. ZhouY. ChenQ. ChenZ. Efficacy and safety of apatinib in treatment of unresectable intrahepatic cholangiocarcinoma: An observational study.Cancer Manag. Res.2020125345535110.2147/CMAR.S254955 32753952
     [Google Scholar]
  66. ShimohiraM. OginoH. KawaiT. SakuraiK. NakagawaM. ShibamotoY. Clinical usefulness of the triaxial system in super-selective transcatheter arterial chemoembolization for hepatocellular carcinoma.Acta Radiol.201253885786110.1258/ar.2012.120044 22850577
     [Google Scholar]
  67. ChoiJ.W. ChungJ.W. ChoY.K. KimY.J. YoonJ.H. KimH.C. JaeH.J. Transarterial chemoembolization for hepatocellular carcinomas with central bile duct invasion: Safety, prognosis, and predictive factors.Cardiovasc. Intervent. Radiol.201538493794510.1007/s00270‑014‑1032‑9 25465065
     [Google Scholar]
  68. BannangkoonK. HongsakulK. TubtaweeT. Mc NeilE. SriplungH. ChongsuwiwatvongV. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma.Asian Pac. J. Cancer Prev.201819123545355010.31557/APJCP.2018.19.12.3545 30583681
     [Google Scholar]
  69. SaccoR. BertiniM. PetruzziP. BertoniM. BargelliniI. BresciG. FedericiG. GambardellaL. MetrangoloS. ParisiG. RomanoA. ScaramuzzinoA. TuminoE. SilvestriA. AltomareE. VignaliC. CapriaA. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study.World J. Gastroenterol.200915151843184810.3748/wjg.15.1843 19370781
     [Google Scholar]
  70. YanL. RenY. QianK. KanX. ZhangH. ChenL. LiangB. ZhengC. Superselective transarterial chemoembolization for unresectable or “ablation unsuitable” hepatocellular carcinoma in the caudate lobe: A real world, single-center retrospective study.Front. Oncol.20211167884710.3389/fonc.2021.678847 34778023
     [Google Scholar]
  71. InuiK. TakahashiY. KomeichiH. KatsutaY. ShimizuS. MizunoK. Successful transcatheter chemoembolization for acute jaundice in a patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis: A case report.J. Nippon Med. Sch.200976421722010.1272/jnms.76.217 19755798
     [Google Scholar]
  72. ChoiJ. RyuJ.K. LeeS.H. HwangJ.H. AhnD.W. KimY.T. YoonY.B. YoonC.J. KangS.G. ChungJ.W. Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization.J. Palliat. Med.20131691026103310.1089/jpm.2013.0067 23888306
     [Google Scholar]
  73. OlivoM. ValenzaF. BuccellatoA. ScalaL. VirdoneR. SciarrinoE. Di PiazzaS. MarroneC. OrlandoA. FuscoG. MadoniaS. CottoneM. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors.Dig. Liver Dis.201042751551910.1016/j.dld.2009.09.012 19914153
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206313132240712101607
Loading
Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 24, 1241 (2024); https://doi.org/10.2174/0118715206313132240712101607
/content/journals/acamc/10.2174/0118715206313132240712101607
/content/journals/acamc/10.2174/0118715206313132240712101607
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bile duct invasion; Hepatocellular carcinoma; hyperbilirubinemia; interventional therapy; obstructive jaundice; percutaneous transhepatic cholangial drainage; transcatheter arterial chemoembolization

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test